- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Country Report: UK
Pharmaceutical Executive
Faced with looming uncertainties triggered by the upcoming Brexit, the United Kingdom’s life sciences sector, which constitutes one of the last big remaining bastions of British industry, is not about to rest on its laurels.
A Vote of Confidence
Britain’s GBP 64 billion (USD 83 billion) life science market has long ranked proudly as one of the most alluring pharma prospects within Europe not just courtesy of a very decent 3.3 percent growth rate, but also because of the country’s heavyweight medical science infrastructure and a well-honed reputation for elite innovation.
“I think one of the tremendous advantages we enjoy here in Britain is that we possess three world-leading assets: our iconic National Health Service (NHS), a thriving life sciences ecosystem, and a formidable academic research base. Each one is recognized as a world-beater in its own right,” resolutely declares parliamentary under secretary of state for health Lord O’Shaughnessy.
Meanwhile, the sector’s value to the national economy stands uncontested. “I consider it absolutely no exaggeration to say that the life sciences sector constitutes one of the last big remaining bastions of British industry. Many of the other traditional heavyweight industries have been gradually hollowed out and relocated to other parts of the globe, but with life sciences, the hub remains staunchly implanted within the UK,” remarks Terry O’Regan, Biogen vice president and managing director of the UK and Irish affiliates.
Yet the overarching vibe is hardly one of a local industry content to rest on its laurels. “With the NHS celebrating its 70th anniversary, a fiercely ambitious and forward-looking Life Sciences Industrial Strategy (LSIS) entering into force, and a historic opportunity to take our sector global with the advent of Brexit, these are profoundly exciting times for anyone involved in the British pharmaceutical or biotech community,” says Mike Thompson, CEO of the Association of the British Pharmaceutical Industry (ABPI).
To view the full article on the UK’s pharma and healthcare markets, produced by Focus Reports and featured in Pharm Exec's September 2018 issue, click here.
To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
